SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934
(State or other jurisdiction of
(Commission File Number)
San Diego, California 92121
(Address of principal executive offices) (Zip Code)
(Registrants telephone number, including area code)
(Former name or former address, if changed since last report)
|Item 4.02. Other Events.|
|Item 8.01. Other Events|
|Item 9.01. Financial Statements and Exhibits|
|ADVENTRX Pharmaceuticals, Inc.
|March 20, 2006||By:||/s/ Carrie E. Carlander|
|Name:||Carrie E. Carlander|
|Title:||Chief Financial Officer, Vice President Finance, Secretary and Treasurer|
|Letter from the registrants auditors dated March 17, 2006, regarding nonreliance on interim review related to the financial statements included in the Quarterly Report on Form 10-Q for the quarter ended September 30, 2005|
|Letter from the registrants auditors dated March 20, 2006, regarding agreement with disclosures made under Item 4.02 of this report|
|Press release of the registrant dated March 20, 2006|
ADVENTRX Pharmaceuticals, Inc.
6725 Mesa Ridge Road, Suite 100
San Diego, CA 92121
|||Condensed consolidated balance sheet as of September 30, 2005,|
|||Condensed consolidated statements of operations for the three and nine months ended September 30, 2005 and for the period from inception (June 12, 1996) through September 30, 2005,|
|||Condensed consolidated statements of shareholders equity (deficit) for the period from January 1, 2005 through September 30, 2005, and|
|||Condensed consolidated statements of cash flows for the nine months ended September 30, 2005 and for the period from inception (June 12, 1996) through September 30, 2005.|
Worldwide Associations through Member Firms of SC International
Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
FOR JULY 2005 FINANCING UNDER EITF 00-19
ADVENTRX Pharmaceuticals is a biopharmaceutical research and development company focused on introducing new technologies for anticancer and antiviral treatments that surpass the performance and safety of existing drugs, by addressing significant problems such as drug metabolism, toxicity, bioavailability and resistance. More information can be found on the Companys Web site at www.adventrx.com.
This press release contains forward-looking statements, within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, regarding ADVENTRX. Such statements are made based on managements current expectations and beliefs. Actual results may vary from those currently anticipated based upon a number of factors, including uncertainties inherent in the drug development process, the timing and success of clinical trials, the validity of research results, and the receipt of necessary approvals from the FDA and other regulatory agencies. For a discussion of such risks and uncertainties, which could cause actual results to differ from those contained in the forward-looking statements regarding ADVENTRX, see the section titled Risk Factors in ADVENTRXs last annual report on Form 10-K, as well as other reports that ADVENTRX files from time to time with the Securities and Exchange Commission. All forward-looking statements regarding ADVENTRX are qualified in their entirety by this cautionary statement. ADVENTRX undertakes no obligation to release publicly any revisions, which may be made to reflect events or circumstances after the date hereof.